Movement Alert｜Duality Biotherapeutics Rises 5.66% in Regular Trading, Share Buyback Plan Triggers Rebound After Multi-Day Selloff

Market Focus05-20 09:32

On May 20, Duality Biotherapeutics rose 5.66% in regular trading, trading at 217.2 HKD/share, with trading volume of 23.78 million HKD. The stock rebounded after falling from approximately 257 HKD to 210.4 HKD over the prior week following the company's announcement on May 12 that it exercised the DB-1311/BNT324 US market exclusive cost and profit/loss sharing option with BioNTech.

On May 19, the company announced a share buyback program of up to USD 40 million, with the board stating that the current trading price does not reflect the company's intrinsic value and business prospects. Additionally, founder Zhu Zhongyuan plans to increase his holdings by up to USD 5 million. The board characterized this as an opportune time for repurchases, noting the buyback is in the overall best interest of shareholders.

Market concerns over short-term capital pressure arising from the obligation to reimburse BioNTech for past development costs following the option exercise appear to be easing. DB-1311/BNT324 is a next-generation ADC candidate targeting B7-H3, currently in Phase 1/2 clinical trials across multiple tumor indications.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1152410415?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-20 09:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152410415","market":"us","top_or_hot":-1,"title":"Movement Alert｜Duality Biotherapeutics Rises 5.66% in Regular Trading, Share Buyback Plan Triggers Rebound After Multi-Day Selloff","media":"Market Focus","content":"<p><p>On May 20, Duality Biotherapeutics rose 5.66% in regular trading, trading at 217.2 HKD/share, with trading volume of 23.78 million HKD. The stock rebounded after falling from approximately 257 HKD to 210.4 HKD over the prior week following the company's announcement on May 12 that it exercised the DB-1311/BNT324 US market exclusive cost and profit/loss sharing option with BioNTech.</p><p>On May 19, the company announced a share buyback program of up to USD 40 million, with the board stating that the current trading price does not reflect the company's intrinsic value and business prospects. Additionally, founder Zhu Zhongyuan plans to increase his holdings by up to USD 5 million. The board characterized this as an opportune time for repurchases, noting the buyback is in the overall best interest of shareholders.</p><p>Market concerns over short-term capital pressure arising from the obligation to reimburse BioNTech for past development costs following the option exercise appear to be easing. DB-1311/BNT324 is a next-generation ADC candidate targeting B7-H3, currently in Phase 1/2 clinical trials across multiple tumor indications.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Duality Biotherapeutics Rises 5.66% in Regular Trading, Share Buyback Plan Triggers Rebound After Multi-Day Selloff</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Duality Biotherapeutics Rises 5.66% in Regular Trading, Share Buyback Plan Triggers Rebound After Multi-Day Selloff\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-20 09:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 20, Duality Biotherapeutics rose 5.66% in regular trading, trading at 217.2 HKD/share, with trading volume of 23.78 million HKD. The stock rebounded after falling from approximately 257 HKD to 210.4 HKD over the prior week following the company's announcement on May 12 that it exercised the DB-1311/BNT324 US market exclusive cost and profit/loss sharing option with BioNTech.</p><p>On May 19, the company announced a share buyback program of up to USD 40 million, with the board stating that the current trading price does not reflect the company's intrinsic value and business prospects. Additionally, founder Zhu Zhongyuan plans to increase his holdings by up to USD 5 million. The board characterized this as an opportune time for repurchases, noting the buyback is in the overall best interest of shareholders.</p><p>Market concerns over short-term capital pressure arising from the obligation to reimburse BioNTech for past development costs following the option exercise appear to be easing. DB-1311/BNT324 is a next-generation ADC candidate targeting B7-H3, currently in Phase 1/2 clinical trials across multiple tumor indications.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1152410415","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152410415","pubTimestamp":1779240740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 20, Duality Biotherapeutics rose 5.66% in regular trading, trading at 217.2 HKD/share, with trading volume of 23.78 million HKD. The stock rebounded after falling from approximately 257 HKD to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"动向提示|Duality Biotherapeutics常规交易涨5.66%股票回购计划引发多日抛售后反弹","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"On May 20, Duality Biotherapeutics rose 5.66% in regular trading, trading at 217.2 HKD/share, with trading volume of 23.78 million HKD. The stock rebounded after falling from approximately 257 HKD to 210.4 HKD over the prior week following the company's announcement on May 12 that it exercised the DB-1311/BNT324 US market exclusive cost and profit/loss sharing option with BioNTech.On May 19, the company announced a share buyback program of up to USD 40 million, with the board stating that the current trading price does not reflect the company's intrinsic value and business prospects. Additionally, founder Zhu Zhongyuan plans to increase his holdings by up to USD 5 million. The board characterized this as an opportune time for repurchases, noting the buyback is in the overall best interest of shareholders.Market concerns over short-term capital pressure arising from the obligation to reimburse BioNTech for past development costs following the option exercise appear to be easing. DB-1311/BNT324 is a next-generation ADC candidate targeting B7-H3, currently in Phase 1/2 clinical trials across multiple tumor indications.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1152410415","isCrawlerRequest":true}